Medtronic Says FDA Clears InPen App, Clearing Path for Glucose Monitoring System Launch

Dow Jones11-20 21:52

By Denny Jacob

Medtronic disclosed that its Smart MDI system with continuous glucose monitoring capabilities is closer to launching after the Food and Drug Administration cleared an associated app.

The medical technology company said Wednesday the FDA cleared its InPen app featuring missed meal dose detection. Medtronic said this paves the way for the launch of its Smart MDI system with Simplera, its continuous glucose monitor.

Medtronic in August disclosed the FDA had approved Simplera.

Medtronic said it will initiate a limited market release beginning with existing standalone continuous glucose monitor and InPen customers followed by a broad commercial launch.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

November 20, 2024 08:52 ET (13:52 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484111374?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 21:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484111374","market":"fut","top_or_hot":-1,"title":"Medtronic Says FDA Clears InPen App, Clearing Path for Glucose Monitoring System Launch","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Medtronic disclosed that its Smart MDI system with continuous glucose monitoring capabilities is closer to launching after the Food and Drug Administration cleared an associated app. \n</p>\n<p>\n  The medical technology company said Wednesday the FDA cleared its InPen app featuring missed meal dose detection. Medtronic said this paves the way for the launch of its Smart MDI system with Simplera, its continuous glucose monitor. \n</p>\n<p>\n  Medtronic in August disclosed the FDA had approved Simplera. \n</p>\n<p>\n  Medtronic said it will initiate a limited market release beginning with existing standalone  continuous glucose monitor and InPen customers followed by a broad commercial launch. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 20, 2024 08:52 ET (13:52 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medtronic Says FDA Clears InPen App, Clearing Path for Glucose Monitoring System Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedtronic Says FDA Clears InPen App, Clearing Path for Glucose Monitoring System Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 21:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Denny Jacob \n\n\n \n\n\n  Medtronic disclosed that its Smart MDI system with continuous glucose monitoring capabilities is closer to launching after the Food and Drug Administration cleared an ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1989764664.SGD","symbol_name":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2484111374","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484111374","pubTimestamp":1732110720,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Medtronic disclosed that its Smart MDI system with continuous glucose monitoring capabilities is closer to launching after the Food and Drug Administration cleared an associated app.The medical technology company said Wednesday the FDA cleared its InPen app featuring missed meal dose detection. Medtronic said this paves the way for the launch of its Smart MDI system with Simplera, its continuous glucose monitor.Medtronic in August disclosed the FDA had approved Simplera.Medtronic said it will initiate a limited market release beginning with existing standalone  continuous glucose monitor and InPen customers followed by a broad commercial launch.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","MDT":"美敦力","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","BK4082":"医疗保健设备","IE00BQXX3D17.EUR":"GUINNESS GLOBAL INNOVATORS \"C\" (EUR) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","IE00BQXX3C00.GBP":"GUINNESS GLOBAL INNOVATORS \"C\" (GBP) ACC","BK4588":"碎股","IE00BQXX3F31.USD":"GUINNESS GLOBAL INNOVATORS \"C\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC"},"translate_title":"美敦力表示FDA批准InPen应用程序，为血糖监测系统的推出扫清了道路","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDT":0.9},"content_text":"By Denny Jacob \n\n\n \n\n\n  Medtronic disclosed that its Smart MDI system with continuous glucose monitoring capabilities is closer to launching after the Food and Drug Administration cleared an associated app. \n\n\n  The medical technology company said Wednesday the FDA cleared its InPen app featuring missed meal dose detection. Medtronic said this paves the way for the launch of its Smart MDI system with Simplera, its continuous glucose monitor. \n\n\n  Medtronic in August disclosed the FDA had approved Simplera. \n\n\n  Medtronic said it will initiate a limited market release beginning with existing standalone  continuous glucose monitor and InPen customers followed by a broad commercial launch. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2024 08:52 ET (13:52 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484111374"}